Geographic Atrophy (GA) Market Research Report Information By Age Group (Above 60 Years and Above 75 Years), By Diagnosis (Fundus Autofluorescence (FAF), Optical Coherence Tomography Angiography (OCT-A), and Multifocal Electroretinography (MfERG)), By Therapeutic Agents Clinical Phase (Late-Stage (Phase III), Phase II, Phase I, and Pre-Clinical Stage & Discovery Candidates) and Region (North America, Europe, Asia-Pacific, and Rest of the World)—Forecast till 2032

Global Geographic Atrophy (GA) Market Overview

Geographic Atrophy (GA) Market Size was valued at USD 18.67 billion in 2021 and is projected to grow from USD 20.07 Billion in 2022 to USD 36.1 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 7.5% during the forecast period (2024 - 2032).The increasing prevalence of geographic atrophy across the globe and the increase in R&D investments by pharmaceutical & biopharmaceutical companies are driving the market growth.

Source Secondary Research, Primary Research, MRFR Database and Analyst Review

Geographic Atrophy (GA) Market Trends

• Growing geriatric population to boost the market growth

Geographic atrophy is one of the most common eye disorders in people over 60. It is the final stage of dry age-related macular degeneration (AMD), and it might lead to irreparable retinal loss. In geographic atrophy, a sharply delineated oval or round area of hypopigmentation occurred, and it has a diameter of at least 175 µm. According to a United Nations (UN) report released in December 2020, there were 727 million individuals aged 65 or over in 2020, and it is predicted that this number would increase to 1.5 billion by the year 2050. The rising life expectancy and falling fertility rates are both contributing to the world's rapidly expanding senior population. Additionally, according to the World Bank, the geriatric population (those over 65) made up 9.3% of the population in 2020, up from 5.9% in 1985.

Furthermore, in developed nations such as the US, the UK, France, Germany, and others have, approximately 1 in 29 people over the age of 75 suffering from geographic atrophy. Thus, older people are at a higher risk of having geographic atrophy. Hence, the increasing geriatric population across the globe is positively impacting the geographic atrophy (GA) market.

The graph that follows illustrates the treatment variations between the pegcetacoplan monthly, every other month, and sham treatment arms overall, as well as according to the tertiles of gender and age. Greater progression (i.e., greater mean change from baseline) is represented by data points on the right-hand side. Moreover, the primary analysis (mixed-effect model) of the sham group in the Phase 2 study shows the geographic atrophy progression as a vertical line. The upper and lower confidence limits of the mean are represented by colored bars.

Geographic Atrophy (GA) Market Segment Insights

Geographic Atrophy (GA) Age Group Insights

The geographic atrophy (GA) market segmentation, based on age group, includes those above 60 years and above 75 years. The above 75 years segment held the majority share in 2021 in the geographic atrophy (GA) market revenue. This is primarily owing to the rising prevalence of geographic atrophy in the above 75 years age group is due to age-related. For instance, according to the Retina Study Group of Portugal, geographic atrophy affects 1.3% of adults between the ages of 75 and 84, rising to approximately 22% by the age of 90.

November 2021 Iveric Bio's(US) avacincaptad pegol (ACP, also known as Zimura), a novel investigational complement C5 inhibitor for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD), has received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA).

Geographic Atrophy (GA) Diagnosis Insights

The geographic atrophy (GA) market segmentation is based on diagnosis includes fundus autofluorescence (FAF), optical coherence tomography angiography (OCT-A), and multifocal electroretinography (MfERG). The optical coherence tomography angiography (OCT-A) segment dominated the market in 2021 and is projected to be the faster-growing segment during the forecast period, 2022-2030. This is due to optical coherence tomography angiography (OCT-A) has evolved as a non-invasive technology for visualizing the retina's and choroid's microvasculature. It is useful for the diagnosis and understanding of many retinal conditions such as geographic atrophy, diabetic retinopathy, dry age-related macular degeneration, wet age-related macular degeneration, vascular occlusions, and others. For instance, the AngioVue OCTA system is based on optical coherence tomography angiography offered by Optovue, Inc. (US).

Geographic Atrophy (GA) Therapeutic Agents Clinical Phase Insights

The geographic atrophy (GA) market data has been bifurcated into late-stage (Phase III), Phase II, Phase I, and pre-clinical stage & discovery candidates. The late-stage (Phase III) segment dominated the market in 2021 and is projected to be the faster-growing segment during the forecast period, 2022-2030. The growth of the biopharmaceutical companies’ segment in the market is mainly due to the Phase III clinical trials used to see if a new medicine or drug combination is better or equal to the current standard of care. For instance, Galderma Laboratories LP (US), an anti-inflammatory Doxycycline, is being studied in phase III clinical trials for the treatment of geographic atrophy. Hence, rising late-stage (Phase III) clinical trials in the geographic atrophy industry are likely to be the key factor driving the growth of this segment in the market.

September 2021 Apellis Pharmaceuticals, Inc. (US) highlighted the best results from the phase III clinical trial for APL-2 Therapy in geographic atrophy and planned to file a new drug application with the FDA in the first half of 2022.

Figure 2 Geographic Atrophy (GA) Market, By Therapeutic Agents Clinical Phase, 2021 & 2030 (USD Billion)

Source Secondary Research, Primary Research, MRFR Database, and Analyst Review

Geographic Atrophy (GA) Regional Insights

By Region, the study segments the market into North America, Europe, Asia-Pacific, and the Rest of the World. The North America geographic atrophy (GA) market is expected to account for USD XX billion in 2021 and is expected to exhibit an XX% CAGR during the study period. This is attributed to the rising investment in the healthcare industry and the presence of major key players in the region such as Apellis Pharmaceuticals, Inc. (US), Iveric Bio (US), Alkeus Pharmaceuticals Inc. (US), and others. Moreover, the rising number of patients suffering from geographic atrophy and growing government initiatives related to geographic atrophy in the region further fuel the growth of the market.

Further, the major countries studied are the U.S., Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 3 GEOGRAPHIC ATROPHY (GA) MARKET SHARE BY REGION 2021 (%)

Source Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe geographic atrophy (GA) market is expected to account for the second-largest market share due to the rising older population, increasing demand for technologically innovative treatment, and growing R&D investment by the biopharmaceutical industry. Further, the Germany geographic atrophy (GA) market is expected to hold third place for the market share, and the UK geographic atrophy (GA) market is expected to fastest-growing market, and which is in the 4th place in the European region. Furthermore, France geographic atrophy (GA) market will hold the 5th place for the market share.

The Asia-Pacific geographic atrophy (GA) market is expected to grow at a CAGR of XX% from 2022 to 2030. This is due to the developing healthcare infrastructure, the establishment of research organizations, and the rising prevalence of AMD disorders among the elderly population. Moreover, China geographic atrophy (GA) market is expected to hold the largest market share, and the India geographic atrophy (GA) market is expected fastest-growing market in the Asia-Pacific region.

For instance, According to World Health Organization (WHO), 90% of the total visually impaired people live in developing countries such as China, India, and others, to become the leader in the geographic atrophy (GA) market.

The Rest of the World includes the Middle East, Africa, and Latin America. Government initiatives to increase medical expenditure and increase healthcare infrastructure in the region contribute to the growth of the geographic atrophy (GA) market.

Geographic Atrophy (GA) Key Market Players & Competitive Insights

The presence of major market players in the Geographic Atrophy (GA) market is characterized by the presence of many international, regional, and local players. growing geriatric population and increasing prevalence of geographic atrophy, and increased healthcare expenditure globally. In addition, the companies are investing in R&D activities to expand their product portfolio for GA, which further drives the growth of the geographic atrophy market. Moreover, the vendors compete based on cost, product quality, reliability, and aftermarket services and try to be the first to bring a treatment for the public. It is crucial for the players to offer cost-efficient and high-quality products for geographic atrophy to succeed in an intensely competitive market environment.

One of the primary business strategies adopted by manufacturers in the geographic atrophy (GA) industry to benefit clients and expand the geographic atrophy (GA) market sector is to manufacture locally to reduce operating costs.

Genentech, Inc. is a biotechnology company dedicated to discovering and developing medicines for patients suffering from serious and potentially fatal illnesses. Genentech is a wholly owned subsidiary of Roche Holding Ltd. Genentech conducts research, develops, manufactures, and distributes human pharmaceuticals to address important medical needs. The company produces animals from gene cells that would not typically be produced by the cell, and it has six offices across the U. S. For instance, in December 2022, Genentech (US) Launches Phase 2a Study of RG6501 (OpRegen) in Patients with Geographic Atrophy. a phase 2a, multicenter, open-label, single-arm clinical study of RG6501 (OpRegen), a retinal pigment epithelial cell therapy. The goal of the trial is to assess the safety and efficacy of OpRegen in up to 60 patients with geographic atrophy (GA) brought on by age-related macular degeneration. The study will examine the best subretinal surgical delivery method.

Also, Iveric Bio (US) is a biopharmaceutical company dedicated to the research and creation of innovative therapies for retinal conditions with unmet medical needs. The company is developing both therapeutic product candidates for age-related retinal diseases and gene therapy product candidates for orphan inherited retinal diseases or IRDs. In June 2022, Iveric Bio's(US) positive topline data from Zimura GATHER2 Phase 3 clinical trial in geographic atrophy.

Key Companies in the Geographic Atrophy (GA) Market includes

• Apellis Pharmaceuticals, Inc. (US)


• Iveric Bio (US)


• Alkeus Pharmaceuticals, Inc. (US)


• Hemera Biosciences LLC (US)


• Allegro Ophthalmics, LLC (US)


• Stealth BioTherapeutics (Cayman Islands)


• Gyroscope Therapeutics Limited (UK)


• F. Hoffmann-La Roche AG (Switzerland)


• Genentech, Inc. (US)


• Gensight Biologics SA (France), among others

Geographic Atrophy (GA) Industry Developments

December 2022 Genentech (US) Launched Phase 2a Study of RG6501 (OpRegen) in Patients with Geographic Atrophy. a phase 2a, multicenter, open-label, single-arm clinical study of RG6501 (OpRegen), a retinal pigment epithelial cell therapy. The goal of the trial is to assess the safety and efficacy of OpRegen in up to 60 patients with geographic atrophy (GA) brought on by age-related macular degeneration. The study will examine the best subretinal surgical delivery method

November 2022 The FDA has approved Apellis Pharmaceuticals Inc’s New Drug Application (NDA) for intravitreal pegcetacoplan for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD)

June 2019 Allegro Ophthalmics (US) Announces Positive topline vision results of phase 2 study evaluating risuteganib in patients with intermediate dry age-related macular degeneration.

September 2021 The U.S. Food and Drug Administration (FDA) has approved the Stealth BioTherapeutics's (Cayman Islands) fast track classification for the treatment of dry geographic atrophy-associated age-related macular degeneration (AMD).

July 2021 Alkeus Pharmaceuticals'(US) C20-D3-Vitamin A (USALK-001) has been approved by the FDA as a revolutionary therapy for the treatment of Stargardt disease.

Geographic Atrophy (GA) Market Segmentation

Geographic Atrophy (GA) Age Group Outlook

• 
  

  Above 60 Years

  
  


• 
  

  Above 75 Years

  
  

Geographic Atrophy (GA) Diagnosis Outlook

• 
  

  Fundus Autofluorescence (FAF)

  
  


• 
  

  Optical Coherence Tomography Angiography (OCT-A)

  
  


• 
  

  Multifocal Electroretinography (MfERG)

  
  

Geographic Atrophy (GA) Therapeutic Agents Clinical Phase Outlook

• 
  

  Late-Stage (Phase III)

  
  


• 
  

  Phase II

  
  


• 
  

  Phase I

  
  


• 
  

  Pre-Clinical Stage & Discovery Candidates

  
  

Geographic Atrophy (GA) Regional Outlook

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America